Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Preliminary results of MK-5172 PN003 (NCT01353911) suggested a possible dose relationship to elevated transaminase levels in treatment with grazoprevir.

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Grazoprevir
DRUG: Placebo to Grazoprevir
DRUG: Peginterferon alfa-2b (Peg-IFN)
DRUG: Ribavirin (RBV)

Sponsor

Merck Sharp & Dohme LLC